NYSE:ELV
Elevance Health Inc (ELV)
Financials 
Technical Analysis 
Jul 13, 2026, 12:00 amThis summary was created by AI, based on 7 opinions in the last 12 months.
Elevance Health Inc (ELV) is currently navigating a challenging landscape within the health insurance sector, which has been significantly impacted by rising medical costs and the post-Covid surge in medical procedures. The experts express a mixed outlook on ELV, highlighting both the difficulties the company faces in a troubled industry and the potential for recovery as it rebounds from a volatile period. The company is seen as offering good value compared to competitors like United Health (UNH), given its strong fee-based model that mitigates some risks. Analysts expect a substantial uptick in premiums in 2026, which could enhance profitability. However, the overall sentiment suggests caution, as the stock may still experience fluctuations before reaching a stable growth trajectory.
Out of favour in 2023. Healthcare is one of the areas where he expects the rotation to go, big opportunity. Stock's flat for last 2 years, but EPS is up 27%. 15x PE this year, 13.5x next year. Estimates of double-digit revenue growth and 15% annual earnings growth. The insurers, in particular, are ripe for a rebound. Yield is 1%.
(Analysts’ price target is $558.02)
Gordon ReidContinues to like it. Healthcare has been in the penalty box the past year. ELV was Anthem. It insures 48 million Americans. Growing 15% annually, but trades at only 14x earnings.
Gordon ReidInsurer margins squeezed as procedures delayed by Covid now go ahead. Market's overreacted to this. Still a good long-term hold. Confident in management. Over next 5-10 years, healthcare spending will be double GDP growth.
Gordon ReidIt is both a growth and value stock being a health insurer for corporations. It also provides management for the Federal Government through Medicare and Medicaid as well as its own networks. It is slowly becoming more vertically integrated. Being more on the defensive side it helps to balance his portfolio. Buy 21 Hold 4 Sell 0
Paul MacDonaldExcellent business with good long term prospects.
Very strong balance sheet.
Large health insurance company with ~45M customers.
Strong management team that is good at running business.
Gordon ReidHealthcare notoriously left out of most recent high-beta rally. Don't give up. Don't chase low-quality, high-beta companies just because they're going up for 6 weeks. Go with good quality companies, and you will be rewarded. He's sticking with it. Demographic tailwind, 6% FCF yield, expects $33 EPS in 2023 which is a 15x PE.
Gordon ReidGordon ReidGordon Reid
Alex RuusGordon Reid'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Trades at 4-5 multiple points lower than UNH, fundamentals are equally good.
Whole group has stalled a bit over medical cost ratios and medical costs in general. Government is repricing programs, and it's affecting margins. Companies will fight through it, trading inexpensively, very solid growth metrics. Not afraid to buy any of them, and his choice is ELV.